Centhaquine for moderate to severe ARDS in ICU patients
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests whether centhaquine is safer and works better than standard care for adults with moderate to severe ARDS in the ICU. It may help improve breathing and outcomes if you qualify based on how severe your lung injury is and how quickly treatment can start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are in the ICU and have moderate to severe ARDS diagnosed by blood-oxygen or oxygen-level measures
- The first study drug dose can start within 48 hours of confirming moderate to severe ARDS
- You need a breathing machine (invasive breathing tube or a non-invasive option like CPAP/NIV)
- You need medicine to support your blood pressure (vasopressors)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug (STSA-1002) for people with severe breathing problems caused by a viral infection. It aims to see if the drug can help improve oxygen levels and reduce the need for a breathing machine.
This trial observes the symptoms, treatments, and recovery of patients with acute respiratory distress syndrome (ARDS), a serious lung condition. It aims to learn more about how different types of breathing support affect outcomes.
This study tests two types of breathing support—CPAP (a mask that pushes air into your lungs) and high-flow nasal oxygen (a special tube in your nose)—to see which works better for people with ARDS, a serious lung condition. It may help you breathe more easily without needing a breathing tube.
This trial tests a drug called aprotinin for people with moderate to severe ARDS who are on a breathing machine. The goal is to see if it helps treat the lung injury.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This Phase 3 study tests whether centhaquine can improve safety and outcomes in adults who are in severe “hypovolemic shock” from low blood volume after an acute event. Participants receive standard emergency shock care, and this trial adds centhaquine to see if it helps better than standard care alone.
Hear when a new Acute Respiratory Distress Syndrome (ARDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.